iCAD (NASDAQ:ICAD - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $4.54 million for the quarter.
iCAD (NASDAQ:ICAD - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The technology company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.02. The business had revenue of $5.41 million during the quarter, compared to analyst estimates of $4.72 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.
iCAD Trading Down 1.4 %
Shares of ICAD stock traded down $0.05 during trading on Friday, reaching $3.63. 484,217 shares of the company's stock traded hands, compared to its average volume of 392,972. iCAD has a 1 year low of $1.18 and a 1 year high of $3.78. The company has a market capitalization of $99.63 million, a P/E ratio of -27.92 and a beta of 1.35. The firm's 50-day moving average is $2.52 and its 200 day moving average is $2.32.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on ICAD shares. Laidlaw reissued a "hold" rating on shares of iCAD in a report on Thursday, April 17th. StockNews.com began coverage on shares of iCAD in a report on Sunday, May 4th. They issued a "sell" rating for the company. BTIG Research downgraded iCAD from a "buy" rating to a "neutral" rating in a research report on Wednesday, April 16th. Finally, Craig Hallum cut iCAD from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 16th.
Check Out Our Latest Research Report on iCAD
iCAD Company Profile
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Articles
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
